Summit Therapeutics Accounts Payable

The latest accounts payable for SMMT is $23M as of June 2026. That compares with $23M in the prior-year period — down 0.4% year over year. Investors often review this figure alongside Summit Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SMMT's accounts payable moved from $23M to $23M — a 0.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Summit Therapeutics's operating scale or balance-sheet position.

A accounts payable figure of $23M for SMMT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SMMT's accounts payable ($23M), review year-over-year change from $23M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.